Search in:

Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 12

Views

CrossRef citations to date

Altmetric

Review

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease

Michael Boyiadzis Assistant Professor of Medicine University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Division of Hematology-Oncology, Department of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA +1 412 648 6589; +1 412 648 6579; [email protected]

, MD MHSc,

Kenneth A Foon Professor of Medicine University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Division of Hematology-Oncology, Department of Medicine, Pittsburgh, Pennsylvania, USA

, MD &

Steven Pavletic National Cancer Institute, National Institutes of Health, Graft-versus-host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, Bethesda, Maryland, USA

, MD

Pages 1789-1797 | Published online: 22 Nov 2007

Cite this article
https://doi.org/10.1517/14712598.7.12.1789

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

MATUTES E, WOTHERSPOON A, CATOVSKY D: Differential diagnosis in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. (2007) 20:367-384.
PubMed Web of Science ®Google Scholar
KEATING MJ, KANTARJIAN H, O'BRIEN S et al.: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. (1991) 9:44-49.
PubMed Web of Science ®Google Scholar
MONTSERRAT E, MORENO C, ESTEVE J et al.: How I treat refractory CLL. Blood (2006) 107:1276-1283.
PubMed Web of Science ®Google Scholar
RAI KR, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343:1750-1757.
PubMed Web of Science ®Google Scholar
KEATING MJ, O'BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23:4079-4088.
PubMed Web of Science ®Google Scholar
CHIORAZZI N, RAI KR, FERRARINI M: Chronic lymphocytic leukemia. N. Engl. J. Med. (2005) 352:804-815.
PubMed Web of Science ®Google Scholar
PACKHAM G, STEVENSON FK: Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology (2005) 114:441-449.
PubMed Web of Science ®Google Scholar
HANADA M, DELIA D, AIELLO A, STADTMAUER E, REED JC: Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood (1993) 82:1820-1828.
PubMed Web of Science ®Google Scholar
PEPPER C, BENTLEY P, HOY T: Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. (1996) 95:513-517.
PubMed Web of Science ®Google Scholar
PEPPER C, THOMAS A, HOY T, COTTER F, BENTLEY P: Antisense-mediated suppression of bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. (1999) 107:611-615.
PubMed Web of Science ®Google Scholar
SCHENA M, LARSSON LG, GOTTARDI D et al.: Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood (1992) 79:2981-2989.
PubMed Web of Science ®Google Scholar
CORDONE I, MASI S, MAURO FR et al.: P53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood (1998) 91:4342-4349.
PubMed Web of Science ®Google Scholar
DOHNER H, FISCHER K, BENTZ M et al.: P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 85:1580-1589.
PubMed Web of Science ®Google Scholar
EL ROUBY S, THOMAS A, COSTIN D et al.: P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of mdr1/mdr3 gene expression. Blood (1993) 82:3452-3459.
PubMed Web of Science ®Google Scholar
LOZANSKI G, HEEREMA NA, FLINN IW et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 103:3278-3281.
PubMed Web of Science ®Google Scholar
STILGENBAUER S, DOHNER H: Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. (2002) 347:452-453.
PubMed Web of Science ®Google Scholar
MOORE JS, PRYSTOWSKY MB, HOOVER RG, BESA EC, NOWELL PC: Defective T cell-mediated, isotype-specific immunoglobulin regulation in B-cell chronic lymphocytic leukemia. Blood (1988) 71:1012-1020.
PubMed Web of Science ®Google Scholar
SCRIVENER S, GODDARD RV, KAMINSKI ER, PRENTICE AG: Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma (2003) 44:383-389.
PubMed Web of Science ®Google Scholar
SCRIVENER S, KAMINSKI ER, DEMAINE A, PRENTICE AG: Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br. J. Haematol. (2001) 112:959-964.
PubMed Web of Science ®Google Scholar
KAY NE, ZARLING JM: Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood (1984) 63:305-309.
PubMed Web of Science ®Google Scholar
ZIEGLER HW, KAY NE, ZARLING JM: Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int. J. Cancer (1981) 27:321-327.
PubMed Web of Science ®Google Scholar
ORSINI E, GUARINI A, CHIARETTI S, MAURO FR, FOA R: The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective t-cell response. Cancer Res. (2003) 63:4497-4506.
PubMed Web of Science ®Google Scholar
ORSINI E, PASQUALE A, MAGGIO R et al.: Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro.Br. J. Haematol. (2004) 125:720-728.
PubMed Web of Science ®Google Scholar
DAMLE RN, WASIL T, FAIS F et al.: IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 94:1840-1847.
PubMed Web of Science ®Google Scholar
HAMBLIN TJ, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK: Unmutated IgV(h) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 94:1848-1854.
PubMed Web of Science ®Google Scholar
KROBER A, SEILER T, BENNER A et al.: V(h) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 100:1410-1416.
PubMed Web of Science ®Google Scholar
OSCIER DG, GARDINER AC, MOULD SJ et al.: Multivariate analysis of prognostic factors in CLL: clinical stage, IgVh gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood (2002) 100:1177-1184.
PubMed Web of Science ®Google Scholar
CRESPO M, BOSCH F, VILLAMOR N et al.: Zap-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. (2003) 348:1764-1775.
PubMed Web of Science ®Google Scholar
ROSENWALD A, ALIZADEH AA, WIDHOPF G et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J. Exp. Med. (2001) 194:1639-1647.
PubMed Web of Science ®Google Scholar
BOSCH F, MUNTANOLA A, GINE E et al.: Clinical implications of zap-70 expressionin chronic lymphocytic leukemia. Cytom. B Clin. Cytom. (2006) 70:214-217.
PubMed Web of Science ®Google Scholar
HAMBLIN TJ, ORCHARD JA, IBBOTSON RE et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood (2002) 99:1023-1029.
PubMed Web of Science ®Google Scholar
JELINEK DF, TSCHUMPER RC, GEYER SM et al.: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haematol. (2001) 115:854-861.
PubMed Web of Science ®Google Scholar
MATRAI Z, LIN K, DENNIS M et al.: CD38 expression and IgVh gene mutation in B-cell chronic lymphocytic leukemia. Blood (2001) 97:1902-1903.
PubMed Web of Science ®Google Scholar
JULIUSSON G, GAHRTON G: Cytogenetics in CLL and related disorders. Baillieres Clin. Haematol. (1993) 6:821-848.
PubMed Web of Science ®Google Scholar
HAMBLIN TJ: Prognostic markers in chronic lympocytic leukaemia. Best Pract. Res. Clin. Haematol. (2007) 20:455-468.
PubMed Web of Science ®Google Scholar
DOHNER H, STILGENBAUER S, BENNER A et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343:1910-1916.
PubMed Web of Science ®Google Scholar
STILGENBAUER S, BULLINGER L, LICHTER P, DOHNER H: Genetics of chronic lymphocytic leukemia: genomic aberrations and V(h) gene mutation status in pathogenesis and clinical course. Leukemia (2002) 16:993-1007.
PubMed Web of Science ®Google Scholar
SHANAFELT TD, GEYER SM, KAY NE: Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood (2004) 103:1202-1210.
PubMed Web of Science ®Google Scholar
STAUDT LM: Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. (2002) 53:303-318.
PubMed Web of Science ®Google Scholar
STAUDT LM: Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. (2003) 348:1777-1785.
PubMed Web of Science ®Google Scholar
BEN-BASSAT I, RAANANI P, GALE RP: Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant. (2007) 39:441-446.
PubMed Web of Science ®Google Scholar
PAVLETIC ZS, BIERMAN PJ, VOSE JM et al.: High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann. Oncol. (1998) 9:1023-1026.
PubMed Web of Science ®Google Scholar
DREGER P, VAN BIEZEN A, BRAND R et al.: Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): the EBMT experience. Blood (2000) 96:A482-A482.
Google Scholar
DREGER P, BUSCH R, STILGENBAUER S et al.: Early autologous stem cell transplantation (sct) in genetically poor-risk chronic lymphocytic leukemia is feasible and effective: results from a prospective multicenter study (GCLLSG CLL3 protocol).Blood (2004) 104:A45.
Google Scholar
DREGER P, STILGENBAUER S, BENNER A et al.: The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the Vh gene mutational status. Blood (2004) 103:2850-2858.
PubMed Web of Science ®Google Scholar
RITGEN M, LANGE A, STILGENBAUER S et al.: Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood (2003) 101:2049-2053.
PubMed Web of Science ®Google Scholar
SCHLOE U, VIEHMANN K, LANGE A, RITGEN M, DREGER P: CD38 expression has no prognostic influence after autologous stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL). Bone Marrow Transplant. (2002) 29:S165.
PubMed Web of Science ®Google Scholar
PAULUS U, SCHMITZ N, VIEHMANN K, VON NEUHOFF N, DREGER P: Combined positive/negative selection for highly effective purging of pbpc grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant. (1997) 20:415-420.
PubMed Web of Science ®Google Scholar
BERKAHN L, SIMPSON D, RAPTIS A, KLINGEMANN HG: In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia. J. Hematother. Stem Cell Res. (2002) 11:315-320.
PubMedGoogle Scholar
BUCKSTEIN R, IMRIE K, SPANER D et al.: Stem cell function and engraftment is not affected by “In vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin. Oncol. (1999) 26:115-122.
PubMed Web of Science ®Google Scholar
MONTILLO M, TEDESCHI A, MIQUELEIZ S et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2006) 24:2337-2342.
PubMed Web of Science ®Google Scholar
DREGER P, VIEHMANN K, VON NEUHOFF N et al.: A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp. Hematol. (2000) 28:1187-1196.
PubMed Web of Science ®Google Scholar
MICHALLET M, THIEBAUT A, DREGER P et al.: Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the european blood and marrow transplantation (EBMT) CLL subcommittee on behalf of the EBMT chronic leukaemias working party (CLWP). Br. J. Haematol. (2000) 108:595-601.
PubMed Web of Science ®Google Scholar
PAVLETIC S, ZHOU GM, SOBOCINSKI K et al.: Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia (2007) (In Press).
Google Scholar
GINE E, MORENO C, ESTEVE J, MONTSERRAT E: The role of stem-cell transplantation in chronic lympocytic leukemia risk-adapted therapy. Best Pract. Res. Clin. Haematol. (2007) 20:529-543.
PubMed Web of Science ®Google Scholar
MORENO C, VILLAMOR N, COLOMER D et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated Vh gene in patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23:3433-3438.
PubMed Web of Science ®Google Scholar
DEMAGALHAES-SILVERMAN M, DONNENBERG A, HAMMERT L et al.: Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant. (1997) 20:175-177.
PubMed Web of Science ®Google Scholar
ESPANOL I, BUCHLER T, FERRA C et al.: Richter's syndrome after allogeneic stem cell transplantation for chronic lymphocytic leukaemia successfully treated by withdrawal of immunosuppression, and donor lymphocyte infusion. Bone Marrow Transplant. (2003) 31:215-218.
PubMed Web of Science ®Google Scholar
RONDON G, GIRALT S, HUH Y et al.: Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. (1996) 18:669-672.
PubMed Web of Science ®Google Scholar
MEHTA J, POWLES R, SINGHAL S et al.: Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant. (1996) 17:371-375.
PubMed Web of Science ®Google Scholar
DREGER P, RITGEN M, BOTTCHER S, SCHMITZ N, KNEBA M: The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia (2005) 19:1135-1138.
PubMed Web of Science ®Google Scholar
MORENO C, VILLAMOR N, COLOMER D et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood (2006) 107:4563-4569.
PubMed Web of Science ®Google Scholar
MATTSSON J, UZUNEL M, REMBERGER M et al.: Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia (2000) 14:247-254.
PubMed Web of Science ®Google Scholar
RITGEN M, STILGENBAUER S, VON NEUHOFF N et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood (2004) 104:2600-2602.
PubMed Web of Science ®Google Scholar
DREGER P, BRAND R, MILLIGAN D et al.: Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia (2005) 19:1029-1033.
PubMed Web of Science ®Google Scholar
KHARFAN-DABAJA MA, ANASETTI C, SANTOS ES: Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol. Blood Marrow Transplant. (2007) 13:373-385.
PubMed Web of Science ®Google Scholar
GRIBBEN JG: Stem-cell transplantation in chronic lympocytic leukaemia. Best Pract. Res. Clin. Haematol. (2007) 20:513-527.
PubMed Web of Science ®Google Scholar
DREGER P, CORRADINI P, KIMBY E et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2007) 21:12-17.
PubMed Web of Science ®Google Scholar
GRIBBEN JG, ZAHRIEH D, STEPHANS K et al.: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 106:4389-4396.
PubMed Web of Science ®Google Scholar
MILLIGAN DW, FERNANDES S, DASGUPTA R et al.: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood (2005) 105:397-404.
PubMed Web of Science ®Google Scholar
MONTSERRAT E, ESTEVE J, SCHMITZ N et al.: Autologous stem-cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients. Blood (1999) 94:A397-A397.
Google Scholar
PAVLETIC ZS, ARROWSMITH ER, BIERMAN PJ et al.: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. (2000) 25:717-722.
PubMed Web of Science ®Google Scholar
TOZE CL, GALAL A, BARNETT MJ, SHEPHERD JD et al.: Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant. (2005) 36:825-830.
PubMed Web of Science ®Google Scholar
PAVLETIC SZ, KHOURI IF, HAAGENSON M et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J. Clin. Oncol. (2005) 23:5788-5794.
PubMed Web of Science ®Google Scholar
SORROR ML, MARIS MB, SANDMAIER BM et al.: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23:3819-3829.
PubMed Web of Science ®Google Scholar
DELGADO J, THOMSON K, RUSSELL N et al.: Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British society of blood and marrow transplantation study. Blood (2006) 107:1724-1730.
PubMed Web of Science ®Google Scholar
BROWN JR, KIM HT, LI S et al.: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol. Blood Marrow Transplant. (2006) 12:1056-1064.
PubMed Web of Science ®Google Scholar
CABALLERO D, GARCIA-MARCO JA, MARTINO R et al.: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin. Cancer Res. (2005) 11:7757-7763.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date